Newly Diagnosed Multiple Myeloma (NDMM), Melphalan+Autologous PBSCT+Placebo Maintenance, Melphalan+Autologous PBSCT+Lenalidomide Maintenance, Phase 3, Immunomodulators (IMiD)
### Instruction:
Identify the study with the following condition. 
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Melphalan+Autologous PBSCT+Placebo Maintenance, Melphalan+Autologous PBSCT+Lenalidomide Maintenance, Phase 3, Immunomodulators (IMiD) 
### Output:
Popular Name is CALGB, Study ID is NCT00114101